Viridian Therapeutics, Inc. announced that Stephen Mahoney has been appointed the company?s Chief Executive Officer effective immediately. Stephen Mahoney?s appointment as Chief Executive Officer combines his leadership and track record of operational execution with the company?s strategy of delivering potentially best-in-class next generation molecules in commercially established disease areas. Viridian?s pipeline is composed of intravenous and subcutaneous IGF-1R inhibitors for patients with TED and, as of today?s announcement, next generation FcRn inhibitors for the treatment of autoimmune diseases.

Scott Myers?s departure as President and CEO of the company was effective as of October 29, 2023. Mr. Mahoney brings more than two decades of experience in the biopharmaceutical industry where he has held a number of strategic, operational, financial, business development and legal roles with regional and global responsibilities. He most recently served as President, Chief Financial and Operating Officer of Magenta Therapeutics.

Prior to Magenta, Mr. Mahoney served as President and Chief Operating Officer of Kiniksa Pharmaceuticals. He also served as Chief Commercial Officer, among other executive titles of increasing responsibility, at Synageva Biopharma Corp. and was a business and transactional attorney at Genzyme Corporation.

Mr. Mahoney holds an M.B.A. and J.D. from Boston College and a B.A. from Colorado College.